We found that serum concentrations of CXCL9, CXCL10, and CCL25 were markedly higher in patients with AIP/IgG4-RD as compared with those with CP and healthy controls, whereas in contrast, serum concentrations of CCL22, a prototypical Th2 chemokine, were not elevated in patients with AIP/IgG4-RD (Figure 11A). This evidence concerns the gene CCL22 and immunoglobulin G4-related sclerosing disease.